Genscript Biotech Corporation

As of December 31, 2025, Genscript Biotech Corporation carries a market capitalization of 2.93B, placing it among publicly traded companies globally. Its enterprise value stands at 2.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genscript Biotech Corporation's next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Genscript Biotech Corporation has 2.18B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Genscript Biotech Corporation maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Genscript Biotech Corporation's stock has gained approximately 107.93% over the past 52 weeks. The 50-day moving average sits at 4.06, while the 200-day moving average is 2.13.

As of December 31, 2025, Genscript Biotech Corporation holds 691.08M in cash and equivalents against 220.30M in total debt, resulting in a net debt position of 44.41M. Total book value stands at 3.37B, with working capital of 305.37M providing operational flexibility.